Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 1039-1049

  Ramesh, Divya ^a   Gamage, Thomas F ^a   Vanuytsel, Tim ^b,c   Owens, Robert A ^a   Abdullah, Rehab A ^a   Niphakis, Micah J ^d   Shea Donohue, Terez ^c   Cravatt, Benjamin F ^d   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF MARYLAND   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

2 AG; anandamide; endocannabinoid; fatty acid amide hydrolase (FAAH); monoacylglycerol lipase (MAGL); morphine withdrawal

Indexed keywords

ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONIC ACID; ESTERASE INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; JZL 184; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE; PF 3845; RIMONABANT; SA 57; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; FACE VALIDITY; FEMALE; HEAD; JUMPING; LOW DRUG DOSE; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

AMIDOHYDROLASES; ANIMALS; BENZODIOXOLES; ENDOCANNABINOIDS; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MONOACYLGLYCEROL LIPASES; MORPHINE; MORPHINE DEPENDENCE; PIPERIDINES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84878576567     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.269     Document Type: Article

References (46)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK et al (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16: 411-420.
2. Ahn K, McKinney MK, Cravatt BF (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707.
3. Bhargava HN (1976). Effect of some cannabinoids on naloxoneprecipitated abstinence in morphine-dependent mice. Psychopharmacology 49: 267-270.
4. Birch EA (1889). The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. The Lancet 133: 625
5. Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML et al (2007). Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend 90: 252-260.
6. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
7. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
8. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
10. Di Marzo V, De Petrocellis L (2010). Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17: 1430-1449.
11. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
12. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 65: 685-694.
13. Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH et al (2010). FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35: 1775-1787.
14. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17: 1723-1726.
15. Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W (2005). Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 48: 1097-1104.
16. Frenois F, Cador M, Caille S, Stinus L, Le Moine C (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377-1389.
17. Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF et al (2012). The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sciences
18. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F et al (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20: 441-458.
19. Hine B, Friedman E, Torrelio M, Gershon S (1975). Morphinedependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 187: 443-445.
20. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y et al (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferatoractivated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55: 85-93.
21. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
22. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL et al (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330: 902-910.
23. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98: 21-27.
24. Koob GF, Le Moal M (2005). Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8: 1442-1444.
25. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ (1998). Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93: 549-559.
26. Leung D, Saghatelian A, Simon GM, Cravatt BF (2006). Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45: 4720-4726.
27. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
28. Long JZ, Nomura DK, Cravatt BF (2009b). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
29. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X et al (2009c). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 106: 20270-20275.
30. Matsuda LA, Bonner TI, Lolait SJ (1993). Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327: 535-550.
31. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski N, Schatz A et al (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
32. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
33. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350.
34. Niphakis MJ, Johnson DS, Ballard TE, Stiff C, Cravatt BF (2012). O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci 3: 418-426.
35. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC et al (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
36. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311.
37. Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M et al (2009). Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiatedependence. Am J Addict 18: 301-308.
38. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG et al (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173-185.
39. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
40. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF et al (2009). Inhibitors of endocannabinoidmetabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11: 342-352.
41. Sciolino NR, Zhou W, Hohmann AG (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
42. Sheldon RJ, Riviere PJ, Malarchik ME, Moseberg HI, Burks TF, Porreca F (1990). Opioid regulation of mucosal ion transport in the mouse isolated jejunum. J Pharmacol Exp Ther 253: 144-151.
43. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227-230.
44. Sugiura T, Kobayashi Y, Oka S, Waku K (2002). Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66: 173-192.
45. Way EL, Loh HH, Shen FH (1969). Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167: 1-8.
46. Wise LE, Long KA, Abdulla RA, Long JZ, Cravatt BF, Lichtman AH (2012). Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice. ACS Chem Neurosci 217: 485-494.